Development of next-generation macromolecular drugs based on the EPR effect: challenges and pitfalls

Bibliography

• VTDeVitaJr, EChu. A history of cancer chemotherapy. Cancer Res 2008;68:8643-53
   PubMed Web of Science ®Google Scholar
• AGilman, FSPhilips. The Biological Actions and Therapeutic Applications of the B-Chloroethyl Amines and Sulfides. Science 1946;103:409-36
   PubMed Web of Science ®Google Scholar
• CMMacleod, ERStone. Differences in the Nature of Antibacterial Action of the Sulfonamides and Penicillin and Their Relation to Therapy. Bull N Y Acad Med 1945;21:375-88
   PubMedGoogle Scholar
• HMaeda, JTakeshita, RKanamaru. A lipophilic derivative of neocarzinostatin. A polymer conjugation of an antitumor protein antibiotic. Int J Pept Protein Res 1979;14:81-7
   PubMedGoogle Scholar
• MXSliwkowski, IMellman. Antibody therapeutics in cancer. Science 2013;341:1192-8
   PubMed Web of Science ®Google Scholar
• BJDruker, STamura, EBuchdunger, et al. Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells. Nat Med 1996;2:561-6
   PubMed Web of Science ®Google Scholar
• MWDeininger, JMGoldman, NLydon, et al. The tyrosine kinase inhibitor CGP57148B selectively inhibits the growth of BCR-ABL-positive cells. Blood 1997;90:3691-8
   PubMed Web of Science ®Google Scholar
• HMKantarjian, TFojo, MMathisen, et al. Cancer drugs in the United States: justum Pretium – the just price. J Clin Oncol 2013;31:3600-4
   PubMed Web of Science ®Google Scholar
• AMohamed, KKrajewski, BCakar, et al. Targeted therapy for breast cancer. Am J Pathol 2013;183:1096-112
   PubMed Web of Science ®Google Scholar
• MHuang, AShen, JDing, et al. Molecularly targeted cancer therapy: some lessons from the past decade. Trends Pharmacol Sci 2014;35:41-50
   PubMed Web of Science ®Google Scholar
• SRicciardi, STomao, Fde Marinis. Toxicity of targeted therapy in non-small-cell lung cancer management. Clin Lung Cancer 2009;10:28-35
   PubMed Web of Science ®Google Scholar
• JWeber. Review: anti-CTLA-4 antibody ipilimumab: case studies of clinical response and immune-related adverse events. Oncologist 2007;12:864-72
   PubMed Web of Science ®Google Scholar
• DFMcDermott, MBAtkins. PD-1 as a potential target in cancer therapy. Cancer Med 2013;2:662-73
   PubMed Web of Science ®Google Scholar
• BVogelstein, NPapadopoulos, VEVelculescu, et al. Cancer genome landscapes. Science 2013;339:1546-58
   PubMed Web of Science ®Google Scholar
• BVogelstein, KWKinzler. Cancer genes and the pathways they control. Nat Med 2004;10:789-99
   PubMed Web of Science ®Google Scholar
• HMaeda. Vascular permeability in cancer and infection as related to macromolecular drug delivery, with emphasis on the EPR effect for tumor-selective drug targeting. Proc Jpn Acad Ser B Phys Biol Sci 2012;88:53-71
   PubMed Web of Science ®Google Scholar
• YNoguchi, JWu, RDuncan, et al. Early phase tumor accumulation of macromolecules: a great difference in clearance rate between tumor and normal tissues. Jpn J Cancer Res 1998;89:307-14
   PubMedGoogle Scholar
• TLammers, FKiessling, WEHennink, et al. Drug targeting to tumors: principles, pitfalls and (pre-) clinical progress. J Control Release 2012;161:175-87
   PubMed Web of Science ®Google Scholar
• HMaeda. The link between infection and cancer: tumor vasculature, free radicals, and drug delivery to tumors via the EPR effect. Cancer Sci 2013;104:779-89
   PubMed Web of Science ®Google Scholar
• HMaeda, JFang, TInutsuka, et al. Vascular permeability enhancement in solid tumor: various factors, mechanisms involved and its implications. Int Immunopharmacol 2003;3:319-28
   PubMed Web of Science ®Google Scholar
• YMatsumura, HMaeda. A new concept for macromolecular therapeutics in cancer chemotherapy: mechanism of tumoritropic accumulation of proteins and the antitumor agent smancs. Cancer Res 1986;46:6387-92
   PubMed Web of Science ®Google Scholar
• HMaeda. SMANCS and polymer-conjugated macromolecular drugs: advantages in cancer chemotherapy. Adv Drug Deliv Rev 2001;46:169-85
   PubMed Web of Science ®Google Scholar
• HMaeda. Macromolecular therapeutics in cancer treatment: the EPR effect and beyond. J Control Release 2012;164:138-44
   PubMed Web of Science ®Google Scholar
• FYuan, MDellian, DFukumura, et al. Vascular permeability in a human tumor xenograft: molecular size dependence and cutoff size. Cancer Res 1995;55:3752-6
   PubMed Web of Science ®Google Scholar
• HHashizume, PBaluk, SMorikawa, et al. Openings between defective endothelial cells explain tumor vessel leakiness. Am J Pathol 2000;156:1363-80
   PubMed Web of Science ®Google Scholar
• KIwai, HMaeda, TKonno. Use of oily contrast medium for selective drug targeting to tumor: enhanced therapeutic effect and X-ray image. Cancer Res 1984;44:2115-21
   PubMed Web of Science ®Google Scholar
• TKonno, HMaeda, KIwai, et al. Selective targeting of anti-cancer drug and simultaneous image enhancement in solid tumors by arterially administered lipid contrast medium. Cancer 1984;54:2367-74
   PubMed Web of Science ®Google Scholar
• TKonno, HMaeda, KIwai, et al. Effect of arterial administration of high-molecular-weight anticancer agent SMANCS with lipid lymphographic agent on hepatoma: a preliminary report. Eur J Cancer Clin Oncol 1983;19:1053-65
   PubMedGoogle Scholar
• SMaki, TKonno, HMaeda. Image enhancement in computerized tomography for sensitive diagnosis of liver cancer and semiquantitation of tumor selective drug targeting with oily contrast medium. Cancer 1985;56:751-7
   PubMed Web of Science ®Google Scholar
• ANagamitsu, KGreish, HMaeda. Elevating blood pressure as a strategy to increase tumor-targeted delivery of macromolecular drug SMANCS: cases of advanced solid tumors. Jpn J Clin Oncol 2009;39:756-66
   PubMed Web of Science ®Google Scholar
• HIPeterson, KLAppelgren. Experimental studies on the uptake and rentention of labelled proteins in a rat tumour. Eur J Cancer 1973;9:543-7
   PubMed Web of Science ®Google Scholar
• HSChoi, WLiu, PMisra, et al. Renal clearance of quantum dots. Nat Biotechnol 2007;25:1165-70
   PubMed Web of Science ®Google Scholar
• HKobayashi, MWBrechbiel. Dendrimer-based macromolecular MRI contrast agents: characteristics and application. Mol Imaging 2003;2:1-10
   PubMedGoogle Scholar
• HMaeda, YMatsumura, TOda, et al. Cancer selective macromolecular therapeusis; tailoring of an antitumor protein drug. Marcel Dekker, Inc, New York and Basel, USA; 1986
   Google Scholar
• AGabizon, RCatane, BUziely, et al. Prolonged circulation time and enhanced accumulation in malignant exudates of doxorubicin encapsulated in polyethylene-glycol coated liposomes. Cancer Res 1994;54:987-92
   PubMed Web of Science ®Google Scholar
• JBWolinsky, YLColson, MWGrinstaff. Local drug delivery strategies for cancer treatment: gels, nanoparticles, polymeric films, rods, and wafers. J Control Release 2012;159:14-26
   PubMed Web of Science ®Google Scholar
• KKnop, RHoogenboom, DFischer, et al. Poly(ethylene glycol) in drug delivery: pros and cons as well as potential alternatives. Angew Chem Int Ed Engl 2010;49:6288-308
   PubMed Web of Science ®Google Scholar
• IBala, SHariharan, MNKumar. PLGA nanoparticles in drug delivery: the state of the art. Crit Rev Ther Drug Carrier Syst 2004;21:387-422
   PubMed Web of Science ®Google Scholar
• BMishra, BBPatel, STiwari. Colloidal nanocarriers: a review on formulation technology, types and applications toward targeted drug delivery. Nanomedicine 2010;6:9-24
   PubMed Web of Science ®Google Scholar
• TLammers. Improving the efficacy of combined modality anticancer therapy using HPMA copolymer-based nanomedicine formulations. Adv Drug Deliv Rev 2010;62:203-30
   PubMed Web of Science ®Google Scholar
• EWvan Etten, MTten Kate, LEStearne, et al. Amphotericin B liposomes with prolonged circulation in blood: in vitro antifungal activity, toxicity, and efficacy in systemic candidiasis in leukopenic mice. Antimicrob Agents Chemother 1995;39:1954-8
   PubMed Web of Science ®Google Scholar
• AAGabizon, YBarenholz, MBialer. Prolongation of the circulation time of doxorubicin encapsulated in liposomes containing a polyethylene glycol-derivatized phospholipid: pharmacokinetic studies in rodents and dogs. Pharm Res 1993;10:703-8
   PubMed Web of Science ®Google Scholar
• MFechtenbaum, MYMd Yusof, PEmery. Certolizumab pegol in rheumatoid arthritis: current update. Expert Opin Biol Ther 2014;14(6):841-50
   PubMed Web of Science ®Google Scholar
• JAShannon, SWCole. Pegloticase: a novel agent for treatment-refractory gout. Ann Pharmacother 2012;46:368-76
   PubMed Web of Science ®Google Scholar
• CHe, YHu, LYin, et al. Effects of particle size and surface charge on cellular uptake and biodistribution of polymeric nanoparticles. Biomaterials 2010;31:3657-66
   PubMed Web of Science ®Google Scholar
• LFBrown, AMDvorak, HFDvorak. Leaky vessels, fibrin deposition, and fibrosis: a sequence of events common to solid tumors and to many other types of disease. Am Rev Respir Dis 1989;140:1104-7
   PubMed Web of Science ®Google Scholar
• KHori, MSuzuki, SSaito, et al. Changes in vessel pressure and interstitial fluid pressure of normal subcutis and subcutaneous tumor in rats due to angiotensin II. Microvasc Res 1994;48:246-56
   PubMed Web of Science ®Google Scholar
• SASkinner, PJTutton, PEO’Brien. Microvascular architecture of experimental colon tumors in the rat. Cancer Res 1990;50:2411-17
   PubMed Web of Science ®Google Scholar
• IAbe, KHori, SSaito, et al. Increased intratumor concentration of fluorescein-isothiocyanate-labeled neocarzinostatin in rats under angiotensin-induced hypertension. Jpn J Cancer Res 1988;79:874-9
   PubMedGoogle Scholar
• MSuzuki, KHori, IAbe, et al. A new approach to cancer chemotherapy: selective enhancement of tumor blood flow with angiotensin II. J Natl Cancer Inst 1981;67:663-9
   PubMed Web of Science ®Google Scholar
• CJLi, YMiyamoto, YKojima, et al. Augmentation of tumour delivery of macromolecular drugs with reduced bone marrow delivery by elevating blood pressure. Br J Cancer 1993;67:975-80
   PubMed Web of Science ®Google Scholar
• JWu, TAkaike, HMaeda. Modulation of enhanced vascular permeability in tumors by a bradykinin antagonist, a cyclooxygenase inhibitor, and a nitric oxide scavenger. Cancer Res 1998;58:159-65
   PubMed Web of Science ®Google Scholar
• MEMarketou, PEVardas. Bradykinin in the treatment of arterial hypertension: friend or foe? Hellenic J Cardiol 2012;53:91-4
   PubMed Web of Science ®Google Scholar
• ANoguchi, TTakahashi, TYamaguchi, et al. Enhanced tumor localization of monoclonal antibody by treatment with kininase II inhibitor and angiotensin II. Jpn J Cancer Res 1992;83:240-3
   PubMedGoogle Scholar
• TSeki, JFang, HMaeda. Enhanced delivery of macromolecular antitumor drugs to tumors by nitroglycerin application. Cancer Sci 2009;100:2426-30
   PubMed Web of Science ®Google Scholar
• HYasuda. Solid tumor physiology and hypoxia-induced chemo/radio-resistance: novel strategy for cancer therapy: nitric oxide donor as a therapeutic enhancer. Nitric Oxide 2008;19:205-16
   PubMed Web of Science ®Google Scholar
• MYJanssens, DLVan den Berge, VNVerovski, et al. Activation of inducible nitric oxide synthase results in nitric oxide-mediated radiosensitization of hypoxic EMT-6 tumor cells. Cancer Res 1998;58:5646-8
   PubMed Web of Science ®Google Scholar
• HYasuda, MYamaya, KNakayama, et al. Randomized phase II trial comparing nitroglycerin plus vinorelbine and cisplatin with vinorelbine and cisplatin alone in previously untreated stage IIIB/IV non-small-cell lung cancer. J Clin Oncol 2006;24:688-94
   PubMed Web of Science ®Google Scholar
• CEstrada, CGomez, CMartin, et al. Nitric oxide mediates tumor necrosis factor-alpha cytotoxicity in endothelial cells. Biochem Biophys Res Commun 1992;186:475-82
   PubMed Web of Science ®Google Scholar
• JBrett, HGerlach, PNawroth, et al. Tumor necrosis factor/cachectin increases permeability of endothelial cell monolayers by a mechanism involving regulatory G proteins. J Exp Med 1989;169:1977-91
   PubMed Web of Science ®Google Scholar
• EFerrero, AVilla, MEFerrero, et al. Tumor necrosis factor alpha-induced vascular leakage involves PECAM1 phosphorylation. Cancer Res 1996;56:3211-15
   PubMed Web of Science ®Google Scholar
• AMEggermont, HSchraffordt Koops, JMKlausner, et al. Isolated limb perfusion with tumor necrosis factor and melphalan for limb salvage in 186 patients with locally advanced soft tissue extremity sarcomas. The cumulative multicenter European experience. Ann Surg 1996;224:756-64; discussion 64-5
   PubMed Web of Science ®Google Scholar
• TSeki, FCarroll, SIllingworth, et al. Tumour necrosis factor-alpha increases extravasation of virus particles into tumour tissue by activating the Rho A/Rho kinase pathway. J Control Release 2011;156:381-9
   PubMed Web of Science ®Google Scholar
• PFailli, AVannacci, LDi Cesare Mannelli, et al. Relaxant effect of a water soluble carbon monoxide-releasing molecule (CORM-3) on spontaneously hypertensive rat aortas. Cardiovasc Drugs Ther 2012;26:285-92
   PubMed Web of Science ®Google Scholar
• RMotterlini, PSawle, JHammad, et al. Vasorelaxing effects and inhibition of nitric oxide in macrophages by new iron-containing carbon monoxide-releasing molecules (CO-RMs). Pharmacol Res 2013;68:108-17
   PubMed Web of Science ®Google Scholar
• NGAbraham, AKappas. Pharmacological and clinical aspects of heme oxygenase. Pharmacol Rev 2008;60:79-127
   PubMed Web of Science ®Google Scholar
• JFang, TAkaike, HMaeda. Antiapoptotic role of heme oxygenase (HO) and the potential of HO as a target in anticancer treatment. Apoptosis 2004;9:27-35
   PubMed Web of Science ®Google Scholar
• AJozkowicz, HWas, JDulak. Heme oxygenase-1 in tumors: is it a false friend? Antioxid Redox Signal 2007;9:2099-117
   PubMed Web of Science ®Google Scholar
• BJMurphy, KRLaderoute, HJVreman, et al. Enhancement of heme oxygenase expression and activity in A431 squamous carcinoma multicellular tumor spheroids. Cancer Res 1993;53:2700-3
   PubMed Web of Science ®Google Scholar
• JFang, HQin, HNakamura, et al. Carbon monoxide, generated by heme oxygenase-1, mediates the enhanced permeability and retention effect in solid tumors. Cancer Sci 2012;103:535-41
   PubMed Web of Science ®Google Scholar
• GBarth, EHuth, FWachsmann. [Experimental investigations on hyperthermia therapy of neoplasms]. Strahlentherapie 1952;88:1-7
   PubMedGoogle Scholar
• GKong, RDBraun, MWDewhirst. Hyperthermia enables tumor-specific nanoparticle delivery: effect of particle size. Cancer Res 2000;60:4440-5
   PubMed Web of Science ®Google Scholar
• GKong, RDBraun, MWDewhirst. Characterization of the effect of hyperthermia on nanoparticle extravasation from tumor vasculature. Cancer Res 2001;61:3027-32
   PubMed Web of Science ®Google Scholar
• BBuckway, NFrazier, AJGormley, et al. Gold nanorod-mediated hyperthermia enhances the efficacy of HPMA copolymer-(90)Y conjugates in treatment of prostate tumors. Nucl Med Biol 2014;41:282-9
   PubMed Web of Science ®Google Scholar
• TLammers. Drug delivery research in Europe. J Control Release 2012;161:151
   PubMed Web of Science ®Google Scholar
• JDaruwalla, MNikfarjam, KGreish, et al. In vitro and in vivo evaluation of tumor targeting styrene-maleic acid copolymer-pirarubicin micelles: survival improvement and inhibition of liver metastases. Cancer Sci 2010;101:1866-74
   PubMed Web of Science ®Google Scholar
• DWNorthfelt, FJMartin, PWorking, et al. Doxorubicin encapsulated in liposomes containing surface-bound polyethylene glycol: pharmacokinetics, tumor localization, and safety in patients with AIDS-related Kaposi’s sarcoma. J Clin Pharmacol 1996;36:55-63
   PubMed Web of Science ®Google Scholar
• VJVenditto, FCSzokaJr. Cancer nanomedicines: so many papers and so few drugs!. Adv Drug Deliv Rev 2013;65:80-8
   PubMed Web of Science ®Google Scholar
• JGong, MChen, YZheng, et al. Polymeric micelles drug delivery system in oncology. J Control Release 2012;159:312-23
   PubMed Web of Science ®Google Scholar
• JAFlygare, THPillow, PAristoff. Antibody-drug conjugates for the treatment of cancer. Chem Biol Drug Des 2013;81:113-21
   PubMed Web of Science ®Google Scholar